Activation of the dopaminergic system underlies the behavioral effects of (+)-amphetamine, and plays a major role in its discriminative stimulus properties. Although serotonin receptors modulate dopamine levels in the brain, and 5-HT 1A and 5-HT 2 receptor agonists do not mimic (+)-amphetamine, pretreatment with 5-HT 2A/2C agonists significantly potentiates the (+)-amphetamine cue. Further, 5-HT 2 antagonists do not modify the discriminative stimulus effect of (+)-amphetamine, but 5-HT 1A antagonists have never been tested in (+)-amphetaminetrained rats. This study sought to characterize the effects of the 5-HT 1A antagonist WAY 100635 on (+)-amphetamineinduced discriminative stimulus effects. Male Sprague-Dawley rats were trained in a two-lever, fixed ratio 50, foodreinforced task with (+)-amphetamine sulfate (1.0 mg/kg, i.p., 30 min pretreatment time) as the discriminative stimulus. Substitution and combination tests with WAY 100635 were then performed. WAY 100635 did not produce substitution in amphetamine-trained rats, but significantly increased behavioral disruption. In combination tests 0.4 and 5.4 mg/kg doses of WAY 100635 potentiated the amphetamine cue. We suggest that low doses of WAY 100635 potentiated the (+)-amphetamine cue by blockade of 5-HT 1A receptors, but stimulation of the dopamine D 4 receptor by higher doses of WAY 100635 may be responsible for potentiation of amphetamine-induced behavioral sensitization. The high percentage of behavioral disruption in substitution tests might suggest that rats trained to discriminate (+)-amphetamine from saline show behavioral sensitization that is not detectable by the drug discrimination assay but may be expressed as hyperactivity and stereotypic behavior that disrupts operant behavior.
Introduction
The monoaminergic psychomotor stimulant drug, amphetamine, increases extracellular levels of synaptic dopamine in the mesocorticolimbic dopaminergic system and thus indirectly serves as a dopaminergic agonist. It is a useful medication in the treatment of attention deficit hyperactivity disorder, narcolepsy, excessive daytime sleepiness, and obesity (Howell and Kimmel, 2008) . The dopamine transporter plays a primary role in the reinforcing and behavioral-stimulant effects of amphetamine in both laboratory animals and humans (Howell and Kimmel, 2008) , although amphetamine also is a substrate for the other monoamine and vesicular monoamine transporters.
The most prominent acute behavioral effects of amphetamine are an increase in locomotor activity, development of behavioral stereotypy, anorexia, and hyperthermia. Amphetamine-induced hyperlocomotion and stereotypy are progressively augmented by repeated administration of amphetamine (Post, 1980; Kuczenski et al., 1982; Robinson and Becker, 1986; Paulson and Robinson, 1991; Robinson and Berridge, 2000) , an effect known as behavioral sensitization, which, once established, is persistent and is thought to represent a permanent change in the neurobiology of the organism (Kalivas and Stewart, 1991) . Repeated administration of amphetamine, however, also results in the development of tolerance to some of the amphetamine-induced effects, including anorexia and stereotypy (Lewander, 1971; Demellweek and Goudie, 1983; Steigerwald et al., 1994) , as well as to its discriminative stimulus properties (Barrett and Leith, 1981) .
Although the reinforcing and behavioral stimulant effects of amphetamine do not seem to depend directly on serotonergic systems, the results of drug interaction studies clearly demonstrate that pharmacological modulation of serotonergic systems can alter the behavioral and neurochemical effects of amphetamine (West et al., 1995) . In general, the blockade of central 5-HT transmission potentiates the stereotypic behavior induced by amphetamine (Dickinson and Curzon, 1983) . Recently, several studies have been focused on the modulatory role of 5-HT 2 receptors in controlling the dopaminergic effects of psychostimulants. For example, data have been reported showing that 5-HT 2A receptor activation increases the release of dopamine into the synaptic cleft, whereas 5-HT 2C receptor activation inhibits it (Alex and Pehek, 2007, Popova et al., 2010) . We previously have shown that preadministration, but not coadministration, of 5-HT 2A/2C agonists to rats potentiates the discriminative cue of amphetamine (Marona-Lewicka and Nichols, 1997) .
Activation of 5-HT 1A somatodendritic autoreceptors located on serotonergic cells in the raphe nuclei acutely decreases forebrain 5-HT, blocks amphetamine-induced hyperactivity (Przegalinski et al., 1997) , and also attenuates the increase in limbic forebrain dopamine levels produced by amphetamine administration (Ichikawa et al., 1995 , Kuroki et al., 1996 . Similarly, coadministration of a 5-HT 1A agonist with psychostimulants (amphetamine, methamphetamine, or methylphenidate) produces an antihyperkinetic and/or calming effect in mice (Tsuchida et al., 2009) , consistent with a decreased ability of amphetamine to increase dopamine levels.
Although (+)-amphetamine is widely used in drug discrimination studies, sensitization to the discriminative stimulus effect of (+)-amphetamine has never been reported with the standard dosing regimen (two to three times per week). Nonetheless, discrimination training with (+)-amphetamine in pigeons, followed by suspension of training while administering repeated high doses of (+)-amphetamine, resulted in an approximately sevenfold increase in the dose of (+)-amphetamine required for amphetamine-associated key responding, demonstrating development of tolerance to the discriminative stimulus effects of (+)-amphetamine (Young et al., 1992) . In rats, tolerance to the discriminative stimulus effect of (+)-amphetamine has also been observed, but only after training was suspended while amphetamine treatment was administered, followed again by discrimination training (Caul et al., 1989) . We hypothesized that during drug discrimination training with amphetamine some plasticity should occur (i.e., sensitization) that might modify behavioral responses, but that such adaptation would be hard to detect using the drug discrimination assay.
In all drug discrimination studies, qualitative and quantitative aspects of the training drug cue are a function of a number of variables, including the specific drug, the specific dose, and the route and timing of administration. Using the drug discrimination paradigm, one can study the degree to which other drugs produce cue states similar to the training drug cue, and the degree to which other drugs might block or potentiate the training druginduced cue in combination tests. Thus, 5-HT 2A/2C agonists do not substitute for amphetamine, nor do 5-HT 2 antagonists block the amphetamine cue (West et al., 1995) , but pretreatment with 5-HT 2A/2C agonists produces a leftward shift in the amphetamine doseresponse cue (Marona-Lewicka and Nichols, 1997).
Preadministration or coadministration of 5-HT 1A agonists had no effect on the amphetamine cue, nor did 5-HT 1A agonists substitute for amphetamine (Przegalinski and Filip, 1997) , but there are no data reported with regard to any influence of 5-HT 1A antagonists on the amphetamine cue in the drug discrimination assay.
WAY 100635 {N-[2-(4-(2-methoxyphenyl)-1-piperazinyl) ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide trihydro-chloride} is a 5-HT 1A antagonist ligand that has been widely used over the past decade (Fletcher et al., 1996) and its effect in behavioral studies is well documented. For example, in drug discrimination experiments, WAY 100635 potently blocked the cue produced by full or partial 5-HT 1A agonists (Sanchez et al., 1996; De Vry and Jentzsch, 1998; Kleven and Koek, 1998; Gommans et al., 2000; Marona-Lewicka and Nichols, 2004) . Nevertheless, we recently demonstrated that at higher doses WAY 100635 produces a robust discriminative stimulus that is insensitive to 5-HT 1A agonist or antagonist treatment, but which can be blocked by dopamine D 4 antagonists ). Moreover, WAY 100635 potentiates the temporally-delayed interoceptive cue produced by lysergic acid diethylamide that is mediated by activation of dopamine D 4 receptors . Further, WAY 100635 is a potent and efficacious dopamine D 4 agonist in heterologous cell expression systems (Chemel et al., 2006) , although Martel et al. (2007) have emphasized that WAY 100635 has much higher selectivity for the h5-HT 1A versus the dopamine D 4 receptor.
Thus, we decided to test WAY 100635 in substitution and combination tests in rats trained to discriminate (+)-amphetamine from saline. For combination tests we chose doses of WAY 100635 previously employed in the drug discrimination assay in our laboratory Nichols, 2004, 2009 ): 0.4 mg/kg as the dose that completely blocks a 5-HT 1A -mediated discriminative cue, and 5.4 mg/kg as the dose that generated a robust discriminative stimulus effect in rats that is mediated by activation of dopamine D 4 receptors . We decided also to test several dopamine D 4 receptor selective compounds in substitution and combination tests in (+)-amphetaminetrained rats.
Methods

Subjects
Male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, Indiana, USA) weighing 180-200 g at the beginning of the study were used as subjects. Rats were trained to discriminate saline from S-(+)-amphetamine sulfate (SAMP; 5.4 mmol/kg, 1.0 mg/kg, i.p.) with a 30 min pretreatment time, using a two-lever, food-reinforced operant conditioning task. All experimental conditions and the feeding procedure were described in detail in our previous paper (Marona-Lewicka and Nichols, 2007).
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None of the rats had previously received drugs or behavioral training. Water was freely available in the individual home cages and a rationed amount of supplemental feed (LabDiet-5001, PMI, Nutrition International, LLC, Brentwood, Missouri, USA) was made available after experimental sessions so as to maintain rats at approximately 80% of their free-feeding weight. Lights were on from 07 : 00 to 19 : 00 h. The laboratory and animal facility temperature was 22-241C and the relative humidity was 40-50%. Experiments were performed between 09 : 00 and 17 : 00 each day, Monday-Friday.
Apparatus
Six standard operant conditioning chambers (model E10-10RF, Coulbourn Instruments, Lehigh Valley, Pennsylvania, USA) consisted of modular test cages enclosed within sound-attenuated cubicles with fans for ventilation, and background white noise. A white house light was centered near the top of the front panel of the cage, which also was equipped with two response levers, separated by a food hopper (combination dipper pellet trough, model E14-06, module size 1/2), all positioned 2.5 cm above the floor. Solid state logic in an adjacent room, interfaced through a Med Associates (Lafayette, Indiana, USA) interface to a personal computer, controlled reinforcement and data acquisition with locally written software.
Procedure
A fixed ratio 50 schedule of food reinforcement (45 mg dustless pellets, Research Diets, Inc., New Jersey, USA) in a two-lever paradigm was used. The details of the drug discrimination procedure have been described elsewhere. (Marona-Lewicka and Nichols, 1994) . At least one drug and one saline session separated each test session. Rats were required to maintain the 85% correct responding criterion on training days to be tested. In addition, test data were discarded when the accuracy criterion of 85% was not achieved on either of the two training sessions following a test session. Training sessions lasted 15 min, and test sessions lasted 5 min and were run under conditions of extinction, with rats removed from the operant chamber when 50 presses were emitted on either lever. In a test session, if 50 presses on one lever were not completed within 5 min the session was ended and scored as a disruption. For substitution tests, drugs were administered i.p. 30 min before test sessions. Combination tests were carried out by administering two different doses of WAY 100635 (0.4 or 5.4 mg/kg) 30 min before different doses of the training drug, that is, 60 min before tests. {2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3methylphenyl) acetamide}, ABT-724 [2-(4-pyridin-2-ylpi perazin-1-ylmethyl)-1H-benzimidazole], and A-381393 {2-[4-(3,4-dimethylphenlyl)piperazin-1-ylmethyl]-1H-ben-zoimidazole} were synthesized in our laboratory, and L-745870 {3-[(4-(4-chlorophenyl)piperazin-1-yl)methyl]-1Hpyrrolo(2,3-b)pyridine} was purchased from TOCRIS (Ellisville, Missouri, USA). All drug solutions were prepared by dissolving the compounds in sterile saline (0.9% NaCl) at a concentration that allowed the appropriate dose to be given in a volume of 1 ml/kg, identical to the volume of the saline injection.
Data analysis
Data from the drug discrimination study were scored in a quantal fashion, with the lever on which the rat first emitted 50 presses in a test session scored as the 'selected' lever. The percentage of rats selecting the drug lever for each dose of test compound was determined. The method of Litchfield and Wilcoxon 1949 was used to determine the median effective dose (ED 50 ) and 95% confidence interval. All dose-dependent curves of (+)-amphetamine used for determination of ED 50 s were later tested for parallelism using a locally-written computer program. For a comparison of response rates, the mean and SEM were calculated for all (+)-amphetamine-trained rats from 22 consecutive drug or saline training sessions (data published in Marona-Lewicka et al., 2005) . Student's t-test was employed for statistical comparison of response-rates between saline and (+)amphetamine training sessions.
Results
Our colonies of rats trained to discriminate (+)-amphetamine from saline generated a dose-dependent discriminative stimulus effect that was stable over time. Table 1 presents examples of ED 50 values calculated twice per year for the last five years for (+)-amphetaminetrained rats. All dose-dependent curves from which the ED 50 was calculated were parallel to each other (lack of significant difference between slopes) and none of the ED 50 values were significantly different.
Rats trained to discriminate (+)-amphetamine administered 30 min before training, however, emitted fewer presses per training session after drug administration than after saline treatments ( Fig. 1 , P < 0.01, Student's t-test, (+)-amphetamine-training vs. saline-training comparison). Similar response rate data in amphetamine-trained rats as of 2004 were presented as part of Figure 1 in Marona-Lewicka et al. (2005) , where we showed a comparison of response rates for several training drugs used in our laboratory. Figure 2 shows the results of substitution tests for WAY 100635 in (+)-amphetamine-trained rats. WAY 100635 did not mimic (+)-amphetamine at any of the doses tested (20% of maximum percentage of rats selecting the drug lever at 5.4 mg/kg), although WAY 100635 produced a dose-dependent increase in behavioral disruption. At WAY 100635 doses of 5.4 mg/kg and higher, more than half of the (+)-amphetamine-trained rats were unable to emit 50 presses during the 5-min test session. All rats treated with WAY 100635 were hyperactive and hyperreflexive, with intense stereotypic sniffing; this hyperactivity is the basis for the inability of the rats to respond in the operant task. Importantly, in amphetamine-naive rats, WAY 100635 has no such locomotor stimulant effects . Table 2 shows results from substitution tests for two selective dopamine D 4 receptor agonists, A-36958 and ABT-724. Neither D 4 agonist mimicked (+)-amphetamine at any of the doses tested, nor did they induce significant disruption of behavior (Table 2) .
Results from combination tests with two different doses of WAY 100635 are presented in Figure. 3. Figure 3a shows a dose-response curve for 0.4 mg/kg of WAY 100635 injected 30 min before different doses of (+)-amphetamine, and Fig. 3b represents the combination of 5.4 mg/kg of WAY 100635 with different doses of (+)-amphetamine. Both doses of WAY 100635 increased selection of the drug appropriate lever compared with (+)-amphetamine alone. Combination of the low dose of WAY 100635 with lower doses of amphetamine (0.125 and 0.25 mg/kg) potentiated the discriminative stimulus effect without significantly affecting response rate. The training dose of amphetamine was not affected by pretreatment with 0.4 mg/kg of WAY 100635 because amphetamine produced a ceiling response at this dose: 100% selection of the drug appropriate lever. Interestingly, however, response rates were elevated up to 26% by this combination. The ED 50 for the combination of 0.4 mg/kg of WAY 100635 with (+)-amphetamine is 0.11 [95% (confidence limit) CL, 0.06-0.22 mg/kg], and for the combination of 5.4 mg/kg of WAY 100635 with (+)-amphetamine is 0.14 (95% CL, 0.08-0.25). In both cases the ED 50 values are lower than for (+)-amphetamine alone (see Table 1 ; ED 50 = 0.24, 95% CL, 0.17-0.34 mg/kg), although neither result is significantly different compared with (+)-amphetamine alone. Pretreatment with 5.4 mg/kg of WAY 100635, followed by the training dose of amphetamine, produced 100% disruption; that is, none of the animals tested were able to emit the required 50 presses during the 5 min test Litchfield and Wilcoxon (1949) . period. All rats receiving this combination showed visible hyperactivity and stereotypic behavior that lasted for at least one hour after the test period (data not shown).
Results from combination tests with the D 4 agonist ABT-724, and the two D 4 antagonists A-381393 and L-745870 are presented in Table 3 . Administration of ABT-724 before amphetamine significantly potentiated drug appropriate responding without increasing the percentage of disruption, and significantly lowered the ED 50 compared with the ED 50 calculated for amphetamine alone. The D 4 antagonists L-745870 and A-381393 partially blocked the discriminative stimulus effects of amphetamine without producing a significant disruptive effect. L-745870 produced a maximum 60% inhibition at 3 mg/kg, whereas A-381393 was able to inhibit the maximum effect of amphetamine response by only 33% (Table 3 ).
Discussion
Drugs that modify both serotonergic and dopaminergic functions may have profound psychopharmacological properties, and can modulate psychostimulant-mediated effects, even if they themselves do not actually mimic the psychostimulant-mediated cue in drug discrimination experiments (Marona-Lewicka and Nichols, 1997; Muller et al., 2007) . WAY 100635 possesses very potent 5-HT 1A receptor antagonist properties, with about 10-fold weaker agonism at dopamine D 4 receptors (Chemel et al., 2006) . Although the low-dose 5-HT 1A antagonist properties of WAY 100635 in drug discrimination studies are well documented (Sanchez et al., 1996; De Vry and Jentzsch, 1998; Kleven and Koek, 1998; Gommans et al., 2000; Marona-Lewicka and Nichols, 2004) , doses of WAY 100635 only about 10-fold higher produce a robust discriminative stimulus effect in rats that is mediated by activation of dopamine D 4 receptors ).
There are only a few drug discrimination studies reporting tests of 5HT 1A or dopamine D 4 agents in amphetamine-trained animals. For example, the discriminative stimulus properties of (+)-amphetamine in rats were not modulated by the 5-HT 1A agonist, 8-OH-DPAT (Przegalinski and Filip, 1997) . This result was later confirmed by Young et al. (2006) , where 8-OH-DPAT neither generalized to (+)-amphetamine when given alone, nor antagonized its stimulus effects when given in combination. In a rhesus monkey study, buspirone, gepirone, and 8-OH-DPAT failed to mimic (+)-amphetamine, but all of these 5-HT 1A receptor agonists inhibited the discriminative stimulus properties of (+)-amphetamine (Nader and Woolverton, 1994) . Most studies, however, have reported that 5-HT 1A agonists do not substitute for psychostimulant drugs, nor do 5-HT 1A antagonists modulate the discriminative stimulus properties of psychostimulants.
We report here that WAY 100635 did not mimic (+)-amphetamine in substitution tests over a range of doses (0.27-10.8 mg/kg); however, in combination tests it potentiated the discriminative stimulus effect produced WAY 100635 was administered 30 min before (+)-amphetamine. Right Y axis and gray symbols show the percentage of rats disrupted. n = 8-12 rats per data point. For the combination of (+)-amphetamine with saline, or (+)-amphetamine alone, the percentage of rats disrupted was always 0% for all doses of (+)-amphetamine. by (+)-amphetamine. Similar results were obtained for the selective dopamine D 4 receptor agonist ABT-724 tested in substitution and combination tests in (+)-amphetamine trained rats, without producing any significant disruption of behavior. The lowest dose of WAY 100635 used in the present experiments was shown previously to be the most effective (100% inhibition) in blocking a 5-HT 1A -mediated cue (Marona-Lewicka and Nichols, 2004) . The highest dose of WAY 100635 used in our combination tests served effectively as a training drug and generated a cue mediated by D 4 dopamine receptor activation ). Thus, we suggest that the 5-HT 1A antagonist effect of low doses of WAY 100635 is responsible for the potentiation of the (+)-amphetamine cue, without affecting response rates, whereas the highest dose of WAY 100635 not only blocked 5-HT 1A receptors, but also effectively stimulated dopamine D 4 receptors, an effect that became evident when rats showed marked hyperactivity and stereotypic behavior during the drug discrimination tests. We note that these robust changes in behavior significantly interfered with operant behavior; they were visible only in animals exposed for longer times to (+)-amphetamine but not in naive rats treated acutely with a combination of WAY 100635 and (+)-amphetamine (data not shown).
WAY 100635 is a potent antagonist at presynaptic and postsynaptic 5-HT 1A receptors, and lacks affinity at other 5-HT receptors (Fletcher et al., 1996) . Although 5-HT 1A antagonists induce only mild behavioral activation in rats (Jackson et al., 1998) , WAY 100635 significantly increased behaviors resembling those induced by dopamine D 1 and D 2 agonists (Jackson et al., 1994) , showing a possible interaction between serotonergic and dopaminergic systems. Indeed, Jackson et al. (1998) later demonstrated that these behaviors could be blocked with the D 1 antagonist SCH 23390 or the D 2 antagonist raclopride.
In the rat, 5-HT 1A receptor agonists elicit a characteristic set of motor behaviors, including the 5-HT syndrome, and under certain conditions can increase locomotor activity (Berendsen et al., 1989; Hillegaart et al., 1989; Evenden and Angeby-Moller, 1990; Renyi, 1991; Mignon and Wolf, 2002) . All these behaviors induced by 5-HT 1A agonists are reversed by pretreatment with WAY 100635, but not by dopaminergic antagonists (see references above). There are conflicting data, however, about the effects of 5-HT 1A agonists on psychostimulant-induced hyperactivity; 8-OH-DPAT inhibits amphetamine-induced hyperactivity (Przegalinski and Filip, 1997) , whereas it potentiated cocaine-induced hyperlocomotion (Muller et al., 2003) . Rats that have been trained to discriminate amphetamine from saline, when treated with WAY 100635 alone or when pretreated with WAY 100635 before amphetamine, show marked, visible changes in behavior, manifested as hyperactivity and elevated stereotypic behavior characteristic of dopaminergic system stimulation, which leads to a high percentage of behavioral disruption (present results). The fact that WAY 100635 does not produce increases in motor behavior in amphetamine-naive rats ), but only in rats that have been given repeated doses of amphetamine, strongly suggests that the present results may be evidence for amphetamineinduced behavioral sensitization.
WAY 100635 is a potent and efficacious dopamine D 4 agonist in heterologous cell expression systems (Chemel et al., 2006) , although Martel et al. (2007) have emphasized that WAY-100635 has much higher activity at the h5-HT 1A receptor. A low dose (up to 0.4 mg/kg) of WAY 100635 that effectively blocks 5-HT 1A -mediated cues did not produce a discriminative stimulus effect by itself, but a 10-fold higher dose of WAY 100635 produces a robust cue that is mediated by stimulation of dopamine Table 3 Results from combination tests of the D 4 dopamine receptor agonist ABT-724 (0.08 mg/kg; 0.2 mmol/kg), and two selective D 4 receptor antagonists A-381393 (3.93 mg/kg; 10 mmol/kg) and L-745870 (3 mg/kg; 6.88 mmol/kg), with different doses of (+)-amphetamine, tested in rats trained to discriminate (+)-amphetamine (1 mg/kg; 5.45 mmol/kg, i.p.) from saline (1998) have demonstrated that the dopamine D 4 receptor plays an important role in the induction of behavioral sensitization by amphetamine and accompanying adaptations in presynaptic and postsynaptic neural systems associated with mesolimbocortical dopamine projections. Moreover, D 4 dopamine receptor knockout mice show an attenuated response to amphetamine-induced hyperlocomotion compared with wild-type mice (Thanos et al., 2010) . The D 4 antagonist A-381393 reversed WAY 100635-induced inhibition of forskolin-stimulated cAMP accumulation (Chemel et al., 2006) , partially inhibited the discriminative stimulus effects of amphetamine, and rightshifted the amphetamine dose-response cue (Table 3) . Although D 4 dopamine agonists (A-36958 and ABT-724) do not substitute in amphetamine-trained animals ( Table 2) , it seems possible that the higher doses of WAY 100635 used in the present experiments potentiate the discriminative stimulus effect of amphetamine through simultaneous inhibition of 5-HT 1A receptors and stimulation of dopamine D 4 receptors.
We report here for the first time that WAY 100635 did not mimic (+)-amphetamine, but when combined with different doses of (+)-amphetamine was able to potentiate drug-appropriate lever selection, especially with lower doses of (+)-amphetamine. Thus, it seems possible that the dual 5-HT 1A antagonist/D 4 agonistic properties of WAY 100635 may regulate the extent of dopamine release by (+)-amphetamine, in some way potentiating its behavioral effects. Pretreatment with 10 mmol/kg of WAY 100635 before 5.4 mmol/kg of (+)-amphetamine (the training dose) produced complete behavioral disruption (Fig. 3b) as a result of a marked increase in locomotor activity. During the combination tests all rats had marked excitation and hyperactivity while being transported, as well as when inside the operant chambers, a behavior that strongly interfered with the learned food-reinforced response. All the animals used in the drug discrimination studies were well adapted to the experimental conditions, all experimental chambers were identical, and injections were always done by the same person in the same surroundings. Thus, we believe environmental factors can be excluded as an explanation for the observed behavioral excitation. Using the drug discrimination assay, however, it is impossible to test acute effects of compounds because animals are chronically exposed to training drugs for at least several weeks.
Our experience from more than two decades in which we have employed (+)-amphetamine-trained rats indicates that neither tolerance nor sensitization develop during normal, regular training with (+)-amphetamine (Steigerwald et al., 1994 , and our observations). Our ED 50 values determined every six months confirmed the stability of the discriminative stimulus effects of (+)-amphetamine. Even after testing a variety of compounds in amphetamine-trained rats, the ED 50 remained unchanged during amphetamine training, suggesting that long-term adaptive changes did not occur, or if they occurred did not affect stimulus control. Further, Steigerwald et al. (1994) have shown stabilization of the ED 50 for (+)-amphetamine even after testing large doses of this drug.
Although drug discrimination is a very powerful method for investigating mechanisms of action for psychoactive drugs, it is not generally useful for exploration of neurochemical changes occurring over prolonged drug administration. That is, rats exposed to prolonged treatment with (+)-amphetamine may develop adaptive changes that are not detectible by measuring discriminative stimulus effects, whereas another behavioral assay may be necessary to identify abnormalities in their behavior. Further studies are indicated to clarify and explore the effect of 5-HT 1A receptor antagonists on amphetamine-induced changes in behavior, as well as the role of the dopamine D 4 receptor in behavioral sensitization.
